"Growth-hormone peptides" is a crowded category with one important internal distinction: a couple have real regulatory standing, and the rest are research compounds. Here's the map.

The main players

  • Sermorelin, a GHRH analog with a prior-approval history, now compounded.
  • Ipamorelin, a growth-hormone secretagogue (ghrelin pathway), not approved.
  • CJC-1295, a long-acting GHRH analog, often discussed with ipamorelin.
  • Tesamorelin, notably FDA-approved for a specific medical indication, unlike the others.

Approved vs research

Tesamorelin stands apart as an approved medication for its indicated use. Sermorelin has the unusual "once approved, now compounded" status. Ipamorelin and CJC-1295 are research peptides without approval. Same category, very different footing.

In this category, the first question isn't which is strongest, it's which is even approved, and for what.
No protocol here

We don't publish doses, schedules, or administration instructions. These compounds aren't FDA-approved, and turning early research into a self-use guide would misrepresent the evidence and the risk. Whether anything is appropriate is a decision for a licensed provider.

Bottom line

Compare the popular pairs in Sermorelin vs Ipamorelin and CJC-1295 vs Ipamorelin, and let a licensed provider guide the rest.